Sirius Genomics Receives NRC-IRAP Funding for Development of New Biomarkers

VANCOUVER, Oct. 5 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

This research funding will be applied to discovery of genomic biomarkers that are predictive of patient response to therapeutics used in critical care medicine leading to improved disease outcomes.

Chris Wagner, President and CEO of Sirius Genomics, comments, "NRC-IRAP's continued support reflects the Canadian Government's commitment to scientific innovation and support for the growth of Canadian companies. Funding from NRC-IRAP will help us advance our pipeline of companion diagnostics."

About Sirius Genomics:

Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.